Medical Condition News

RSS

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

Halozyme Therapeutics, Inc. and ViroPharma Incorporated, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous formulation of Cinryze .

12 May 2011

Visual perception and attention can be changed by passive stimulation

What was previously known from animal studies has thus for the first time been demonstrated for human individuals too. "The findings open new perspectives in the intervention and treatment of visual perceptual disorders, because the changes can be induced quite simply" said Dr. Christian Beste of the RUB Institute of Cognitive Neuroscience.

12 May 2011

School-based prevention programs can help reduce alcohol problems in young people

School prevention programs aimed at curbing alcohol misuse in children are somewhat helpful, enough so to deserve consideration for widespread use, according to a large, international systematic review.

12 May 2011

Scientists to discuss latest autism research findings at IMFAR meeting

The 10th Annual International Meeting for Autism Research will host more than 1900 researchers, delegates, autism specialists, and students in the world's largest gathering of researchers and clinicians devoted to a better understanding of autism. The meeting will be held at the Manchester Grand Hyatt from May 12-14, 2011.

12 May 2011

Valor Medical's Neucrylate AN device receives CE Mark approval for treating cerebral aneurysms

Valor Medical announced today that it has received CE Mark approval for Neucrylate AN for treating cerebral aneurysms.

12 May 2011

Injecting botox in 'trigger points' of pericraneal and neck muscles reduces migraine frequency

Scientists at the University of Granada have confirmed that injecting a local anesthetic or botulinum toxin (botox) into certain points named "trigger points" of the pericraneal and neck muscles reduce migraine frequency among migraine sufferers. University of Granada researchers have identified the location of these trigger points -which activation results in migraine- and their relationship with the duration and severity of this condition.

11 May 2011

MHI team uses cryoablation to successfully treat atrial fibrillation

The electrophysiology team at the Montreal Heart Institute (MHI) used cryoablation (ablation using cold) to treat a patient suffering from atrial fibrillation, the most common form of cardiac arrhythmia, and one associated with significant morbidity.

From Medtronic 11 May 2011

Catasys commences enrollment for integrated substance dependence program in Nevada

Catasys, Inc. announced today that it has launched and begun enrollment for its integrated substance dependence program, called OnTrak™, in Nevada.

11 May 2011

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced a second drug from its cardiometabolic program, SPC4955 into Phase 1 clinical trials, for the treatment of high cholesterol.

11 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

SAFC, Oncolytics Biotech sign commercial supply agreement for REOLYSIN

Oncolytics Biotech Inc. today announced that it has entered into a commercial supply agreement with SAFC, a Division of Sigma-Aldrich Corporation, for the commercial manufacture of REOLYSIN, Oncolytics proprietary reovirus.

11 May 2011

AspirinWorks Test now available in greater Boston and surrounding area

A simple urine test that measures aspirin effect is now available in the greater Boston and surrounding area. The AspirinWorks Test is available to eastern Massachusetts and southern New Hampshire area doctors through Diagnostic Laboratory Medicine.

11 May 2011

Two new policy briefs on California health reform law

According to two new policy briefs from the UCLA Center for Health Policy Research, the majority of state residents likely to be eligible for federally mandated health insurance coverage initiatives in California in 2014 are also those who may be least likely to excessively use costly health services: men, singles and those of working age.

11 May 2011

TSA, Psyadon Pharmaceuticals partner for ecopipam clinical trial in Tourette Syndrome

The national Tourette Syndrome Association and Psyadon Pharmaceuticals Inc. are pleased to announce their collaboration on a clinical trial to determine the potential efficacy of a novel drug, ecopipam, for managing the symptoms of the neurological disorder Tourette Syndrome.

11 May 2011

Amylin, JDRF collaborate to investigate combination therapy for type 1 diabetes treatment

The Juvenile Diabetes Research Foundation and Amylin Pharmaceuticals, Inc. announced today that they have entered into a research collaboration agreement to provide financial support for a series of clinical studies to investigate the feasibility of mixing pramlintide, an analog of the human hormone amylin, with insulin to treat type 1 diabetes.

11 May 2011

Impax Pharmaceuticals initiates IPX159 Phase I study in Restless Legs Syndrome

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., announced the successful filing of an Investigational New Drug Application for IPX159 in Restless Legs Syndrome and initiated a Phase I study.

11 May 2011

Heart docs dismiss bias claims stemming from industry support of meeting

Doctors said the heart society meeting was an important opportunity to learn about new research in their field and see new products on the market. Unlike in many other areas of medicine, they said, electrophysiologists work hand-in-hand with device company representatives to program implantable defibrillators and diagnose problems.

11 May 2011

Engineers develop novel hybrid HMI for hands-free control of electric powered wheelchairs

For people with severe physical disabilities, such as spinal cord injury, quadriplegia and hemiplegia or amputation, current technology for controlling a wheelchair or mobility scooter is wholly inadequate.

11 May 2011

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that GATTEX, a novel, recombinant analog of human glucagon-like peptide 2, was found to effectively and safely reduce parenteral support volume in adult short bowel syndrome-intestinal failure patients.

11 May 2011

Study: Many patients screened for colon cancer more often than recommended

Many patients are getting screened for colorectal cancer more often than guidelines recommend, hints a new study.

11 May 2011

Medical Condition News

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

Visual perception and attention can be changed by passive stimulation

School-based prevention programs can help reduce alcohol problems in young people

Scientists to discuss latest autism research findings at IMFAR meeting

Valor Medical's Neucrylate AN device receives CE Mark approval for treating cerebral aneurysms

Injecting botox in 'trigger points' of pericraneal and neck muscles reduces migraine frequency

MHI team uses cryoablation to successfully treat atrial fibrillation

Catasys commences enrollment for integrated substance dependence program in Nevada

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

SAFC, Oncolytics Biotech sign commercial supply agreement for REOLYSIN

AspirinWorks Test now available in greater Boston and surrounding area

Two new policy briefs on California health reform law

TSA, Psyadon Pharmaceuticals partner for ecopipam clinical trial in Tourette Syndrome

Amylin, JDRF collaborate to investigate combination therapy for type 1 diabetes treatment

Impax Pharmaceuticals initiates IPX159 Phase I study in Restless Legs Syndrome

Heart docs dismiss bias claims stemming from industry support of meeting

Engineers develop novel hybrid HMI for hands-free control of electric powered wheelchairs

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

Study: Many patients screened for colon cancer more often than recommended

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News